Retension Pharmaceuticals (RTSN) closed at $11.04 on November 6, 2026, up 3.0% from the previous close, on volume of 29,401 shares (30-day average 143,281).
Data as of November 6, 2026.
Globe Newswire (Thu, 5-Nov 8:02 AM ET)
Retension’s Hypertension Trial Stays Active: What RTSN Investors Should Watch
TipRanks (Wed, 4-Nov 11:32 AM ET)
TipRanks (Mon, 2-Nov 4:20 AM ET)
Retension Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (PDE-5) inhibitor designed to reduce blood pressure.
Retension Pharmaceuticals trades on the NASDAQ stock market under the symbol RTSN.
As of November 6, 2026, RTSN stock price climbed to $11.04 with 29,401 million shares trading.
RTSN has a market cap of $91.98 million. This is considered a Micro Cap stock.
RTSN support price is $9.76 and resistance is $11.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RTSN shares will trade within this expected range on the day.
